Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Oricell Therapeutics
company
About
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy.
- 101 - 250
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- ¥200M
- Industries
- Health Care,Pharmaceutical,Product Research
- Founded date
- Jan 1, 2015
- Number Of Employee
- 101 - 250
- Operating Status
- Active
OriCell Therapeutics develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
¥203M $120M
Oricell Therapeutics has raised a total of
¥203M $120M
in funding over 2 rounds. Their latest funding was raised on
Aug 1, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 1, 2022 | Series B | $120M | 4 | — | — | Detail |
| Jan 18, 2021 | Series A | ¥200M | 1 | — | — | Detail |
| Jun 12, 2018 | Angel | ¥3M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
6
Oricell Therapeutics is funded by 6 investors.
Suzhou Fund
and Boquan Equity Investment Management
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series B |
|
|
— | Series B |
|
|
— | Series B |
|
|
— | Series B |
|
|
— | Series A |
|
|
— | Angel |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
